Evidence based PCOs
Upcoming SlideShare
Loading in...5
×
 

Evidence based PCOs

on

  • 2,067 views

 

Statistics

Views

Total Views
2,067
Views on SlideShare
2,051
Embed Views
16

Actions

Likes
3
Downloads
80
Comments
0

1 Embed 16

http://ebwhs.com 16

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Evidence based PCOs Evidence based PCOs Presentation Transcript

  • Evidence Based PCOs
  • Introduction
    • Polycystic ovarian syndrome (PCOS) affects 4% to 12% of women of reproductive age.
    • hallmarks of the disease are hyperandrogenism and chronic anovulation
  • Changing Approach
    • management not only toward treating infertility and improving the often troublesome hirsutism but also toward the long-term risks associated with IR.
  • Moreover
    • Recent data suggest that women with PCOS are at increased risk for preterm labor, preeclampsia, and gestational diabetes, though the evidence for increased miscarriage rates is less certain (Legro , 2007)
  • Ideal design to get best Evidence
    • A randomised controlled trial (RCT) with large numbers and, ideally, three groups is needed:
    • women with PCOS taking medication,
    • women with PCOS taking no treatment
    • non-PCOS women
  • metformin vs. both clomiphene and combination therapy
    • Metformin is not an effective addition to clomifene citrate as the primary method of inducing ovulation in women with polycystic ovary syndrome
  • NEJM, 2007
    • The live-birth rate was 22.5% (47 of 209 subjects) in the clomiphene group, 7.2% (15 of 208) in the metformin group, and 26.8% (56 of 209) in the combination-therapy group
    • (P<0.001 for metformin vs. both clomiphene and combination therapy; P=0.31 for clomiphene vs. combination therapy).
  • BMJ, 2007
    • Clomid alone vs clomid + metformin
    • no significant differences in either rate of ongoing pregnancy (40% v 46%)
  • However
    • gastrointestinal side effects were more frequent with metformin arm
  • Accordingly
    • Addition of metformin to clomid is not recommended
  • Recommendations
    • based on good and consistent scientific evidence (Level A)
    • All women with polycystic ovary syndrome (PCOS) should be screened for glucose intolerance with a 2-hour glucose level after a 75-g fasting glucose challenge
    • All women with PCOS should be screened for dyslipidemia with a fasting lipoprotein profile, including total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride determinations.
  • LIFESTYLE MODIFICATION WEIGHT LOSS
    • A 3 to 6 month trial of aggressive lifestyle modification may be a prudent first step before considering medications.
    • However, many patients will have difficulty in achieving weight loss
    • Use of clomiphene citrate is appropriate because it effectively results in pregnancy in women with PCOS. (Hughes, 1997)
    • The following recommendations are based on limited or inconsistent scientific evidence (Level B)
  • Long term
    • Improvements in insulin sensitivity, by weight loss may favorably improve many risk factors for diabetes and cardiovascular disease in women with PCOS.
    • When using gonadotropins to induce ovulation, low-dose therapy is recommended because it offers a high rate of monofollicular development and a significantly lower risk of ovarian hyperstimulation in women with PCOS.
  • Ovarian drilling
    • The clear benefit and role of surgical therapy in ovulation induction in women with PCOS is uncertain.
    • The following recommendations are based primarily on consensus and expert opinion (Level C)
  • Hirsutism
    • Combining medical interventions may be the most effective way to treat hirsutism. Combined therapy with an ovarian suppression agent and an antiandrogen appears effective in treating hirsutism in women with PCOS. The best pill or antiandrogen is unknown.
  • Ablation techniques
    • The ideal choice of ablative procedures for long-term management of hirsutism in women with PCOS is unknown.
  • During Pregnancy
    • The effects of insulin-sensitizing agents on early pregnancy are unknown; metformin appears safe, but any additional effect at reducing pregnancy loss is uncertain
  • Side Effects of Medication
    • Progestins . Use of medroxyprogesterone acetate is associated with decreases in sex hormone binding globulin (SHBG). Progestin-only oral contraceptives are associated with high incidence of breakthrough bleeding.
  • Gn
    • Use of gonadotrophins can result in ovarian hyperstimulation syndrome
  • Insulin-sensitizing agents
    • The most common adverse reactions of metformin are gastrointestinal symptoms (diarrhea, nausea, vomiting, abdominal bloating, flatulence, and anorexia).
    • Troglitazone had been associated with an increased risk of hepatotoxicity and was removed from the market.
  • Cosmetic management of hirsutism
    • Plucking can cause folliculitis, pigmentation, and scarring.
    • Electrolysis is tedious, its success is highly operator-dependent, and it may be impractical for treating large numbers of hairs.
    • Laser treatment is also operator-dependent and multiple treatments may be necessary
  • Future
    • There are few data to support treatment during pregnancy with metformin in women with PCOS to prevent pregnancy loss or pregnancy complications. (Legro, 2007)
  • it may be time to take PCOS in pregnancy seriously
  • Thank You